The SEC says the trading app misled users by claiming to be commission-free, while charging extra on execution prices that it got back from the market makers.
You might also be interested in reading Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion.